By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Eisai Inc. 

100 Tice Boulevard

Woodcliff Lake  New Jersey  07677  U.S.A.
Phone: 201-692-1100 Fax: 201-692-1804

Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai’s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company’s areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit

For more information about Eisai, please visit

Key Statistics

Ownership: Subsidiary

Web Site: Eisai Inc.
Employees: Approximately 2,600
Symbol: ESALF.PK


Company News
Eisai Inc. (ESALF.PK) Launches "Search For The Next Medikidz Star" Contest For Kids Living With Epilepsy 10/24/2014 8:50:23 AM
Eisai Inc. (ESALF.PK) And Arena Pharmaceuticals, Inc. (ARNA) Announce Presentation Of Lorcaserin Hcl Data At The American College Of Clinical Pharmacy Annual Meeting 10/13/2014 7:38:28 AM
Eisai Inc. (ESALF.PK) And Arena Pharmaceuticals, Inc. (ARNA) Announce Publication Of Pooled Phase 3 Clinical Trial Analysis Of BELVIQ® (Lorcaserin Hcl) CIV In Postgraduate Medicine 10/10/2014 9:52:26 AM
Eisai Inc. (ESALF.PK) Release: Lorcaserin HCl Data To Be Presented At The American Society of Bariatric Physicians' 64th Annual Obesity & Associated Conditions Symposium 9/10/2014 8:46:59 AM
Eisai Inc. (ESALF.PK) Sells U.S. Rights To Zonegran® (zonisamide) Capsules To Concordia Pharmaceuticals 9/3/2014 11:40:18 AM
Eisai Inc. (ESALF.PK) And Arena Pharmaceuticals, Inc. (ARNA) Announce Publication Of Post-Hoc Analyses Of Lorcaserin Phase 3 Clinical Trial Results In Obesity 7/30/2014 8:22:26 AM
Arena Pharmaceuticals, Inc. (ARNA) Reports That Eisai Inc. (ESALF.PK) Completes Planned Increase In Sales Force For BELVIQ® (Lorcaserin Hcl) CIV 7/10/2014 10:09:06 AM
Eisai Inc. (ESALF.PK) Release: Survey Presented At The Joint Annual Meeting Of The International Congress Of Endocrinology And The Endocrine Society (ICE/ENDO 2014) Shows Most Of Those Affected By Obesity Are Not Taking Steps To Lose Weight 6/23/2014 6:13:36 AM
FDA Green Lights Eisai Inc. (ESALF.PK)'s ALOXI ®To Prevent Nausea And Vomiting Due To Chemotherapy In Kids 5/28/2014 2:27:34 PM
Eisai Inc. (ESALF.PK) Highlights New Research At 50th American Society of Clinical Oncology Annual Meeting 5/15/2014 7:08:12 AM